|Bid||23.93 x 900|
|Ask||24.00 x 800|
|Day's range||23.90 - 24.89|
|52-week range||23.22 - 77.72|
|Beta (5Y monthly)||0.86|
|PE ratio (TTM)||N/A|
|Earnings date||03 May 2023 - 08 May 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||55.94|
Guardant Health (GH) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
PALO ALTO, Calif., March 21, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has announced support for an investigator initiated study led and conducted by The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) to evaluate patient compliance with a blood-based test for colorectal cancer (CRC) screening. In this study, The Ohio State University Guardant Shield Colorectal Canc
Key Insights Institutions' substantial holdings in Guardant Health implies that they have significant influence over...